Abstract

Zimmer Biomet will report fourth-quarter results on February 10, 2026, Pre-Market; this preview outlines consensus for revenue, margins, and adjusted EPS, compares them with the prior quarter, and synthesizes institutional commentary since January 01, 2026 through February 03, 2026.

Market Forecast

Market consensus for the current quarter anticipates revenue of $2.23 billion, up 10.76% year over year, EBIT of $0.66 billion with an estimated 6.31% year-over-year increase, and adjusted EPS of $2.40 with an estimated 4.40% year-over-year increase. Based on the company’s last report cadence, investors also expect the gross profit margin profile to remain in the low-70.00% range and the net profit margin in the low-teens, consistent with recent performance, while adjusted EPS tracks above $2.00 on sustained procedure volumes. The main business outlook centers on continued recovery and stability in reconstructive procedures, with knees and hips supported by steady hospital utilization and a resilient backlog. The most promising segment is the knee franchise, which generated $0.79 billion last quarter; ongoing mix improvements and pricing discipline suggest sustained mid-single-digit to high-single-digit growth year over year.

Last Quarter Review

Zimmer Biomet’s prior quarter delivered revenue of $2.00 billion, a gross profit margin of 72.05%, GAAP net profit attributable to the parent company of $0.23 billion with a net profit margin of 11.54%, and adjusted EPS of $1.90, each improving year over year on healthy elective procedure activity. A notable financial highlight was the better-than-anticipated profitability with EBIT of $0.53 billion, which modestly exceeded prior estimates and reflected disciplined cost control. By business line, knees contributed $0.79 billion, hips delivered $0.51 billion, and the surgical, sports medicine, biologics, foot and ankle, extremities, and trauma portfolio combined for $0.54 billion, underscoring balanced demand across reconstructive and extremities.

Current Quarter Outlook (with major analytical insights)

Core Reconstructive Portfolio

Zimmer Biomet’s core reconstructive portfolio—knees and hips—remains the anchor for near-term financial performance, driving the bulk of revenue and underpinning operating leverage. Forecast revenue growth of 10.76% year over year reflects consistent procedure volumes and a relatively stable pricing backdrop as hospitals normalize procurement and staffing. Margin resilience should follow from a 72.00%–plus gross margin baseline in the last quarter, with mix tailwinds from premium implants and robotics-enabled procedures. Investors should watch for commentary on implant pull-through from the installed base of enabling technologies, as this can magnify ASPs and protect share in competitive tenders. An additional dynamic to monitor is inventory positioning at distributors and hospitals; clean channel inventories would support smoother sequential growth without requiring outsized promotional activity, helping sustain the low-teens net margin profile.

Most Promising Growth Vector: Knees

The knee franchise, which generated $0.79 billion in the last quarter, carries the strongest potential to outpace consolidated growth, aided by a robust global replacement market and favorable demographics. In the current quarter, the growth setup appears supported by steady U.S. elective procedure flow and improving international volumes, which together can drive high-single-digit expansion for knees on a year-over-year basis. Continuous enhancements around cementless options, personalized instrumentation, and the integration of digital planning tools can lift utilization and support price integrity. From a profitability standpoint, better manufacturing yields and logistics normalization can preserve gross margin despite input cost variability. The key variable is operating room throughput: if hospitals maintain scheduling efficiency, revenue conversion from backlog should remain healthy and EPS delivery can align with the $2.40 estimate.

Stock Price Drivers This Quarter

Three themes are poised to influence the stock around the print: the cadence of revenue growth versus the 10.76% estimate, the stickiness of gross margin near the low-70.00% range, and EPS leverage relative to the $2.40 consensus. A print that pairs double-digit revenue growth with stable gross margin would reinforce the thesis of durable demand and disciplined execution, potentially widening the path to sustained mid-teens operating margins over time. Conversely, any indication of pricing pressure in core joints or slower-than-expected robotics pull-through could compress EPS versus expectations. Management’s color on capital budgets, procedure pipelines, and supply chain costs will be critical to refining full-year modeling assumptions for revenue growth and margin trajectory.

Analyst Opinions

Across recent institutional commentary, the majority of views are bullish, emphasizing consistent procedural recovery, balanced growth across knees, hips, and extremities, and constructive EPS progression as cost discipline supports operating leverage. Well-followed analysts highlight that the estimated $2.23 billion revenue and $2.40 EPS imply manageable execution risk given the track record of slight outperformance on profitability and a prior-quarter EBIT of $0.53 billion that exceeded estimates. The bullish case also underscores an expected 6.31% year-over-year increase in EBIT to $0.66 billion, with margin durability aided by premium product mix and steady hospital throughput. On balance, the prevailing view holds that Zimmer Biomet can meet or modestly exceed consensus on both revenue and EPS if procedure momentum and margin stability persist into February 10, 2026 Pre-Market.